Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity

Inclusion Criteria

• •PATIENTS
• •Adult patients, male or female
• •Diagnosis of migraine, with or without aura, or chronic migraine, according to the International Classification of Headaches (ICHD-3.)
• •Diagnosis of migraine with onset at an age of less than 50 years
• •Depressive symptoms in patients defined as a Patient Health Questionnaire PHQ-9 scale score ≥5
• •Complete details of migraine history and frequency of monthly migraine days in the past month
• •clinical indication to start fremanezumab therapy to prevent migraine in patients naïve to monoclonal antibodies targeting the CGRP pathway
• •In case of migraine preventive therapy and concomitant antidepressants, stability for at least 8 weeks prior to enrollment.
• •Presence of a caregiver (see definition below) of the patient
• •80% compliance with diary and ability to complete the scale to provide written informed consent.
• •INFORMAL CAREGIVERS:
• •Adult subjects, male or female.
• •Informal caregiver is defined as a person--spouse/partner, parent, child/child, sibling--who cares for the migraine patient, sharing the same household and performing various functions, from basic daily needs to socio-economic activities)
• •RSS score ≥ 1
• •80% compliance with completion scale ability to provide written informed consent